Search results
Results from the WOW.Com Content Network
Pyrosequencing has also been used to analyze bisulfite-treated DNA without using methylation-specific PCR. [7] [8] Following PCR amplification of the region of interest, pyrosequencing is used to determine the bisulfite-converted sequence of specific CpG sites in the region. The ratio of C-to-T at individual sites can be determined ...
The company Pyrosequencing AB in Uppsala, Sweden was founded with venture capital provided by HealthCap in order to commercialize machinery and reagents for sequencing short stretches of DNA using the pyrosequencing technique. Pyrosequencing AB was listed on the Stockholm Stock Exchange in 1999. It was renamed to Biotage in 2003. [7]
The Illumina Methylation Assay using the Infinium I platform uses 'BeadChip' technology [clarification needed] to generate a comprehensive genome-wide profiling of human DNA methylation. Similar to bisulfite sequencing and pyrosequencing , this method quantifies methylation levels at various loci within the genome .
DNA methylation levels in Drosophila melanogaster are nearly undetectable. [86] ... Pyrosequencing of bisulfite treated DNA. This is the sequencing of an amplicon ...
The first few steps of COBRA, and the molecular changes caused by each step to methylated and unmethylated CpG sites. Combined Bisulfite Restriction Analysis (or COBRA) is a molecular biology technique that allows for the sensitive quantification of DNA methylation levels at a specific genomic locus on a DNA sequence in a small sample of genomic DNA. [1]
Pyrosequencing uses luciferase to generate light for detection of the individual nucleotides added to the nascent DNA, and the combined data are used to generate sequence reads. [81] This technology provides intermediate read length and price per base compared to Sanger sequencing on one end and Solexa and SOLiD on the other.
Overall, MGMT methylation is associated with prolonged patient survival in clinical prediction models. [10] For testing of the MGMT promoter methylation status in the clinical setting, DNA-based methods such as methylation-specific polymerase chain reaction (MS-PCR) or pyrosequencing are preferred over immunohistochemical or RNA- based assays. [11]
In a study which tested the methylation status of the MGMT promoter on 19 colorectal samples, 8 samples were found to be methylated. [8] Another study compared the predictive power of MGMT promoter methylation in 83 high grade glioma patients obtained by either MSP, pyrosequencing, and HRM. The HRM method was found to be at least equivalent to ...